Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: A retrospective study

Journal of Medical Imaging and Radiation Oncology

Volumn 59, Issue 2, 2015, Pages 248-254

  Grenfell, Solveig ^a,d   Roos, Daniel ^a,b   Rijken, James ^a,e   Higgs, Braden ^a   Kirkwood, Ian ^a,b,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Division of Medical Imaging   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e Adelaide Radiotherapy Centre   (Australia)

Author keywords

effective half life; I 131 ablation; recombinant human thyroid stimulating hormone; thyroid cancer; thyroid hormone withdrawal

Indexed keywords

CREATININE; IODINE 131; RECOMBINANT THYROTROPIN; THYROID HORMONE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT PROTEIN; THYROTROPIN;

ABLATION THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIFFERENTIATED THYROID CANCER; DRUG HALF LIFE; FEMALE; HOSPITAL ADMISSION; HUMAN; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; THYROID HORMONE WITHDRAWAL; ADJUVANT THERAPY; HALF LIFE TIME; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HALF-LIFE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926484679     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12238     Document Type: Article

References (30)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
2. Pacini F, Castagna MG, Brilli L, Pentheroudakis G,. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): 110-119. vii.
3. McDougall IR, Weigel RJ,. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opin Oncol 2001; 13: 39-43.
4. Duntas LH, Biondi B,. Short-term hypothyroidism after levothyroxine withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 2007; 156: 13-19.
5. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-932.
6. Taïeb D, Sebag F, Cherenko M, et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009; 71: 115-123.
7. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878-884.
8. Tagay S, Herpertz S, Langkafel M, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755-763.
9. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 337: 1674-1685.
10. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663-1672.
11. Borget I, Corone C, Nocaudie M, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007; 156: 531-538.
12. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005; 12: 49-64.
13. Menzel C, Kranert WT, Dobert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131-I. J Nucl Med 2003; 44: 1065-1068.
14. Tuttle MR, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008; 49: 764-770.
15. Ma C, Xie J, Liu W, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database Syst Rev 2010; (11): Art. No.: CD008302. doi: 10.1002/14651858.CD008302.pub2.
16. Tu J, Wang S, Huo Z, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol 2014; 110: 25-30.
17. Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM,. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 2011; 96: 2105-2111.
18. Kreisman SH, Hennessey JV,. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med 1999; 159: 79-82.
19. Remy H, Borget I, Leboulleux S, et al. 131-I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 2008; 49: 1445-1450.
20. Taïeb D, Sebag F, Farman-Ara B, et al. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 2010; 95: 3283-3290.
21. Rosario PW, Borges MA, Purisch S,. Preparation with recombinant human thyroid-stimulating hormone for thyroid ablation with 131-I is associated with lowered radiotoxicity. J Nucl Med 2008; 49: 1776-1782.
22. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47: 648-654.
23. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Scheme (PBS): thyrotropin alfa. Accessed 2014 May 11. Available from: http://www.pbs.gov.au/medicine/item/2700D.
24. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR,. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-414.
25. Mernagh P, Suebwongpat A, Silverberg J, Weston A,. Cost effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective. Value Health 2010; 13: 180-187.
26. Borget I, Remy H, Chevalier J, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and Thyrogen. Eur J Nucl Med Mol Imaging 2008; 35: 1457-1463.
27. Wang TS, Cheung K, Mehta P, Roman SA, Walker HD, Sosa JA,. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab 2010; 95: 1672-1680.
28. Australian Radiation Protection and Nuclear Safety Agency. Recommendations for the discharge of patients undergoing treatment with radioactive substances. Radiation Protection Series RPS No. 4. Canberra: Australian Radiation Protection and Nuclear Safety Agency, 2002.
29. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H,. Low vs high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS ONE 2008; 3: e1885.
30. Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60, and 100 mCi. Thyroid Res 2010; 3: 9.